{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T18:39:14Z","timestamp":1793817554802,"version":"4.6.1"},"reference-count":36,"publisher":"American Society of Hematology","issue":"12","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2013,3,21]]},"abstract":"<jats:title>Key Points<\/jats:title>\n               <jats:p>The increased expression of PI3K p110\u03b1 in mantle cell lymphoma, particularly at relapse, suggests a role for p110\u03b1 in disease progression. A high PIK3CA\/PIK3CD ratio identifies patients unlikely to respond to p110\u03b4 inhibitors and supports use of dual p110\u03b1\/p110\u03b4 inhibitors in MCL.<\/jats:p>","DOI":"10.1182\/blood-2012-10-460832","type":"journal-article","created":{"date-parts":[[2013,1,23]],"date-time":"2013-01-23T08:00:58Z","timestamp":1358928058000},"page":"2274-2284","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":103,"title":["P110\u03b1-mediated constitutive PI3K signaling limits the efficacy of p110\u03b4-selective inhibition in mantle cell lymphoma, particularly with multiple relapse"],"prefix":"10.1182","volume":"121","author":[{"given":"Sunil","family":"Iyengar","sequence":"first","affiliation":[{"name":"Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, Charterhouse Square, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Clear","sequence":"additional","affiliation":[{"name":"Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, Charterhouse Square, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Csaba","family":"B\u00f6d\u00f6r","sequence":"additional","affiliation":[{"name":"Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, Charterhouse Square, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lenushka","family":"Maharaj","sequence":"additional","affiliation":[{"name":"Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, Charterhouse Square, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abigail","family":"Lee","sequence":"additional","affiliation":[{"name":"Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, Charterhouse Square, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Calaminici","sequence":"additional","affiliation":[{"name":"Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, Charterhouse Square, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet","family":"Matthews","sequence":"additional","affiliation":[{"name":"Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, Charterhouse Square, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sameena","family":"Iqbal","sequence":"additional","affiliation":[{"name":"Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, Charterhouse Square, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Auer","sequence":"additional","affiliation":[{"name":"Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, Charterhouse Square, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Gribben","sequence":"additional","affiliation":[{"name":"Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, Charterhouse Square, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Joel","sequence":"additional","affiliation":[{"name":"Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, Charterhouse Square, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111823242182100_B1","author":"Martin"},{"key":"2019111823242182100_B2","author":"Fernandez"},{"issue":"5","key":"2019111823242182100_B3","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1182\/blood-2006-04-015586","article-title":"Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma.","volume":"108","author":"Rudelius","year":"2006","journal-title":"Blood"},{"issue":"10","key":"2019111823242182100_B4","doi-asserted-by":"crossref","first-page":"5142","DOI":"10.1182\/blood-2007-07-103481","article-title":"Distinct functional significance of Akt and mTOR constitutive activation in mantle cell lymphoma.","volume":"111","author":"Dal Col","year":"2008","journal-title":"Blood"},{"issue":"4","key":"2019111823242182100_B5","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1111\/j.1365-2141.2005.05630.x","article-title":"Gene expression profiling of mantle cell lymphoma cells reveals aberrant expression of genes from the PI3K-AKT, WNT and TGFbeta signalling pathways.","volume":"130","author":"Rizzatti","year":"2005","journal-title":"Br J Haematol"},{"issue":"12","key":"2019111823242182100_B6","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1038\/onc.2008.502","article-title":"Styryl sulfonyl compounds inhibit translation of cyclin D1 in mantle cell lymphoma cells.","volume":"28","author":"Prasad","year":"2009","journal-title":"Oncogene"},{"issue":"18","key":"2019111823242182100_B7","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.4161\/cc.7.18.6733","article-title":"GSK-3beta inhibition: at the crossroad between Akt and mTOR constitutive activation to enhance cyclin D1 protein stability in mantle cell lymphoma.","volume":"7","author":"Dal Col","year":"2008","journal-title":"Cell Cycle"},{"issue":"1","key":"2019111823242182100_B8","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1182\/blood-2010-04-189977","article-title":"Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era.","volume":"117","author":"P\u00e9rez-Gal\u00e1n","year":"2011","journal-title":"Blood"},{"issue":"1","key":"2019111823242182100_B9","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1006\/excr.1999.4701","article-title":"Signaling by distinct classes of phosphoinositide 3-kinases.","volume":"253","author":"Vanhaesebroeck","year":"1999","journal-title":"Exp Cell Res"},{"issue":"4","key":"2019111823242182100_B10","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/nri1056","article-title":"PI3K in lymphocyte development, differentiation and activation.","volume":"3","author":"Okkenhaug","year":"2003","journal-title":"Nat Rev Immunol"},{"issue":"3","key":"2019111823242182100_B11","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/nrm3290","article-title":"PI3K signalling: the path to discovery and understanding.","volume":"13","author":"Vanhaesebroeck","year":"2012","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"9","key":"2019111823242182100_B12","doi-asserted-by":"crossref","first-page":"4330","DOI":"10.1073\/pnas.94.9.4330","article-title":"P110delta, a novel phosphoinositide 3-kinase in leukocytes.","volume":"94","author":"Vanhaesebroeck","year":"1997","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"2019111823242182100_B13","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1182\/blood-2005-07-3041","article-title":"Key role of the p110delta isoform of PI3K in B-cell antigen and IL-4 receptor signaling: comparative analysis of genetic and pharmacologic interference with p110delta function in B cells.","volume":"107","author":"Bilancio","year":"2006","journal-title":"Blood"},{"issue":"5670","key":"2019111823242182100_B14","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1126\/science.1096502","article-title":"High frequency of mutations of the PIK3CA gene in human cancers.","volume":"304","author":"Samuels","year":"2004","journal-title":"Science"},{"key":"2019111823242182100_B15","author":"Psyrri"},{"issue":"35","key":"2019111823242182100_B16","doi-asserted-by":"crossref","first-page":"13057","DOI":"10.1073\/pnas.0802655105","article-title":"PTEN-deficient cancers depend on PIK3CB.","volume":"105","author":"Wee","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"2019111823242182100_B17","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1158\/0008-5472.CAN-09-2525","article-title":"Isoform-specific phosphoinositide 3-kinase inhibitors exert distinct effects in solid tumors.","volume":"70","author":"Edgar","year":"2010","journal-title":"Cancer Res"},{"issue":"7205","key":"2019111823242182100_B18","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/nature07091","article-title":"Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis.","volume":"454","author":"Jia","year":"2008","journal-title":"Nature"},{"key":"2019111823242182100_B19","author":"Rao"},{"issue":"6","key":"2019111823242182100_B20","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.ccr.2009.10.016","article-title":"Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation.","volume":"16","author":"Jaiswal","year":"2009","journal-title":"Cancer Cell"},{"issue":"2","key":"2019111823242182100_B21","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1182\/blood-2010-03-275305","article-title":"CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability.","volume":"117","author":"Lannutti","year":"2011","journal-title":"Blood"},{"key":"2019111823242182100_B22","author":"Kahl"},{"issue":"18","key":"2019111823242182100_B23","doi-asserted-by":"crossref","first-page":"5522","DOI":"10.1021\/jm800295d","article-title":"The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer.","volume":"51","author":"Folkes","year":"2008","journal-title":"J Med Chem"},{"issue":"1","key":"2019111823242182100_B24","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1042\/BJ20110502","article-title":"A drug targeting only p110\u03b1 can block phosphoinositide 3-kinase signalling and tumour growth in certain cell types.","volume":"438","author":"Jamieson","year":"2011","journal-title":"Biochem J"},{"issue":"5","key":"2019111823242182100_B25","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/nm1232","article-title":"PI 3-kinase p110beta: a new target for antithrombotic therapy.","volume":"11","author":"Jackson","year":"2005","journal-title":"Nat Med"},{"key":"2019111823242182100_B26","author":"Carvalho"},{"issue":"4","key":"2019111823242182100_B27","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1158\/0008-5472.CAN-09-3419","article-title":"Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma.","volume":"70","author":"Fern\u00e0ndez","year":"2010","journal-title":"Cancer Res"},{"issue":"4","key":"2019111823242182100_B28","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.tibs.2005.02.008","article-title":"Signalling by PI3K isoforms: insights from gene-targeted mice.","volume":"30","author":"Vanhaesebroeck","year":"2005","journal-title":"Trends Biochem Sci"},{"issue":"3","key":"2019111823242182100_B29","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.cell.2004.07.018","article-title":"Gene targeting: attention to detail.","volume":"118","author":"Vanhaesebroeck","year":"2004","journal-title":"Cell"},{"issue":"5","key":"2019111823242182100_B30","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nrm2882","article-title":"The emerging mechanisms of isoform-specific PI3K signalling.","volume":"11","author":"Vanhaesebroeck","year":"2010","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"19","key":"2019111823242182100_B31","doi-asserted-by":"crossref","first-page":"7809","DOI":"10.1073\/pnas.0700373104","article-title":"Class IA phosphoinositide 3-kinases are obligate p85-p110 heterodimers.","volume":"104","author":"Geering","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"issue":"134","key":"2019111823242182100_B32","doi-asserted-by":"crossref","first-page":"ra60","DOI":"10.1126\/scisignal.2001104","article-title":"The PI3K isoforms p110alpha and p110delta are essential for pre-B cell receptor signaling and B cell development.","volume":"3","author":"Ramadani","year":"2010","journal-title":"Sci Signal"},{"issue":"Pt 24","key":"2019111823242182100_B33","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1242\/jcs.032763","article-title":"Distinct roles of class IA PI3K isoforms in primary and immortalised macrophages.","volume":"121","author":"Papakonstanti","year":"2008","journal-title":"J Cell Sci"},{"issue":"15s","key":"2019111823242182100_B34","article-title":"A first-in-human phase I study to evaluate the pan-PI3K inhibitor GDC-0941 administered QD or BID in patients with advanced solid tumors [abstract].","volume":"28","author":"Wagner","year":"2010","journal-title":"J Clin Oncol"},{"issue":"1","key":"2019111823242182100_B35","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ccr.2009.04.012","article-title":"AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer.","volume":"16","author":"Vasudevan","year":"2009","journal-title":"Cancer Cell"},{"issue":"23","key":"2019111823242182100_B36","doi-asserted-by":"crossref","first-page":"5123","DOI":"10.1016\/j.febslet.2005.07.096","article-title":"Comparison of phosphatidylinositol-3-kinase signalling within a panel of human colorectal cancer cell lines with mutant or wild-type PIK3CA.","volume":"579","author":"Morrow","year":"2005","journal-title":"FEBS Lett"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/121\/12\/2274\/1364308\/2274.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/121\/12\/2274\/1364308\/2274.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T04:24:40Z","timestamp":1574137480000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/121\/12\/2274\/31448\/P110%CE%B1mediated-constitutive-PI3K-signaling-limits"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3,21]]},"references-count":36,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2013,3,21]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2012-10-460832","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,3,21]]}}}